收费全文 | 25007篇 |
免费 | 2797篇 |
国内免费 | 104篇 |
耳鼻咽喉 | 205篇 |
儿科学 | 1006篇 |
妇产科学 | 686篇 |
基础医学 | 3560篇 |
口腔科学 | 439篇 |
临床医学 | 3687篇 |
内科学 | 5269篇 |
皮肤病学 | 591篇 |
神经病学 | 2595篇 |
特种医学 | 600篇 |
外国民族医学 | 4篇 |
外科学 | 2615篇 |
综合类 | 215篇 |
一般理论 | 5篇 |
预防医学 | 2472篇 |
眼科学 | 309篇 |
药学 | 1700篇 |
中国医学 | 20篇 |
肿瘤学 | 1930篇 |
2023年 | 251篇 |
2022年 | 153篇 |
2021年 | 712篇 |
2020年 | 647篇 |
2019年 | 972篇 |
2018年 | 1106篇 |
2017年 | 883篇 |
2016年 | 909篇 |
2015年 | 957篇 |
2014年 | 1169篇 |
2013年 | 1671篇 |
2012年 | 1982篇 |
2011年 | 1896篇 |
2010年 | 1230篇 |
2009年 | 1060篇 |
2008年 | 1538篇 |
2007年 | 1500篇 |
2006年 | 1394篇 |
2005年 | 1309篇 |
2004年 | 1220篇 |
2003年 | 1092篇 |
2002年 | 1002篇 |
2001年 | 218篇 |
2000年 | 194篇 |
1999年 | 203篇 |
1998年 | 226篇 |
1997年 | 183篇 |
1996年 | 133篇 |
1995年 | 169篇 |
1994年 | 148篇 |
1993年 | 118篇 |
1992年 | 110篇 |
1991年 | 108篇 |
1990年 | 100篇 |
1989年 | 88篇 |
1988年 | 85篇 |
1987年 | 61篇 |
1986年 | 70篇 |
1985年 | 67篇 |
1984年 | 81篇 |
1983年 | 75篇 |
1982年 | 88篇 |
1981年 | 88篇 |
1980年 | 63篇 |
1979年 | 37篇 |
1978年 | 41篇 |
1977年 | 45篇 |
1976年 | 62篇 |
1975年 | 44篇 |
1974年 | 47篇 |
Methods: Three to six months after the end of the intervention, we interviewed 32 of the caregivers, leaders, and physicians participating in the trial, in five focus groups. We used thematic content analysis.
Results: The analysis yielded two main themes: (1) a systematic reflection method enhanced learning at work; (2) the structure of the approach helped staff to cope with NPS in residents with dementia.
Conclusion: TIME shifts the way of learning for the staff from a traditional to a more innovative and reflection-based learning through a process of learning how to learn at work. The staff's experienced increased coping in their approach to complex problems. Our results emphasise the importance of a structured and biopsychosocial approach to NPS in clinical practice. Future research should explore models for integrating situated learning in daily routines in nursing homes. 相似文献
Background
The International Agency for Research on Cancer (IARC) has recently classified glyphosate as a Group 2A ‘probably carcinogenic to humans’. Due to this carcinogenic classification and resulting international debate, there is an increased demand for studies evaluating human health effects from glyphosate exposures. There is currently limited information on human exposures to glyphosate and a paucity of data regarding glyphosate's biological half-life in humans.Objective
This study aims to estimate the human half-life of glyphosate from human urine samples collected from amenity horticulture workers using glyphosate based pesticide products.Methods
Full void urine spot samples were collected over a period of approximately 24?h for eight work tasks involving seven workers. The elimination time and estimation of the half-life of glyphosate using three different measurement metrics: the unadjusted glyphosate concentrations, creatinine corrected concentrations and by using Urinary Excretion Rates (UER) (μg L?1, μmol/mol creatinine and UER μg L?1) was calculated by summary and linear interpolation using regression analysis.Results
This study estimates the human biological half-life of glyphosate as approximately 5 ½, 10 and 7 ¼ hours for unadjusted samples, creatinine corrected concentrations and by using UER (μg L?1, μmol/mol creatinine, UER μg L?1), respectively. The approximated glyphosate half-life calculations seem to have less variability when using the UER compared to the other measuring metrics.Conclusion
This study provides new information on the elimination rate of glyphosate and an approximate biological half-life range for humans. This information can help optimise the design of sampling strategies, as well as assisting in the interpretation of results for human biomonitoring studies involving this active ingredient. The data could also contribute to the development or refinement of Physiologically Based PharmacoKinetic (PBPK) models for glyphosate. 相似文献About 20–25% of patients experience weight regain (WR) or insufficient weight loss (IWL) after bariatric metabolic surgery (BS). Therefore, we aimed to retrospectively assess the effectiveness of adjunct treatment with the GLP-1 receptor agonist semaglutide in non-diabetic patients with WR or IWL after BS.
Materials and MethodsPost-bariatric patients without type 2 diabetes (T2D) with WR or IWL (n?=?44) were included in the analysis. The primary endpoint was weight loss 3 and 6 months after initiation of adjunct treatment. Secondary endpoints included change in BMI, HbA1c, lipid profile, hs-CRP, and liver enzymes.
ResultsPatients started semaglutide 64.7?±?47.6 months (mean?±?SD) after BS. At initiation of semaglutide, WR after post-bariatric weight nadir was 12.3?±?14.4% (mean?±?SD). Total weight loss during semaglutide treatment was???6.0?±?4.3% (mean?±?SD, p?<?0.001) after 3 months (3.2 months, IQR 3.0–3.5, n?=?38) and???10.3?±?5.5% (mean?±?SD, p?<?0.001) after 6 months (5.8 months, IQR 5.8–6.4, n?=?20). At 3 months, categorical weight loss was?>?5% in 61% of patients,?>?10% in 16% of patients, and?>?15% in 2% of patients. Triglycerides (OR?=?0.99; p?<?0.05), ALT (OR?=?0.87; p?=?0.05), and AST (OR?=?0.89; p?<?0.05) at baseline were negatively associated with weight loss of at least 5% at 3 months’ follow-up (p?<?0.05).
ConclusionTreatment options to manage post-bariatric excess weight (regain) are scarce. Our results imply a clear benefit of adjunct treatment with semaglutide in post-bariatric patients. However, these results need to be confirmed in a prospective randomized controlled trial to close the gap between lifestyle intervention and revision surgery in patients with IWL or WR after BS.
Graphical abstract 相似文献